

Published in final edited form as:

Biomol Concepts. 2012 December 1; 3(6): 571–580. doi:10.1515/bmc-2012-0030.

Modulation of host microtubule dynamics by pathogenic bacteria

Girish K. Radhakrishnan and Gary A. Splitter*

Department of Pathobiological Sciences, University of Wisconsin-Madison, Madison, WI 53706, USA

Abstract

The eukaryotic cytoskeleton is a vulnerable target of many microbial pathogens during the course of infection. Rearrangements of host cytoskeleton benefit microbes in various stages of their infection cycle such as invasion, motility, and persistence. Bacterial pathogens deliver a number of effector proteins into host cells for modulating the dynamics of actin and microtubule cytoskeleton. Alteration of the actin cytoskeleton is generally achieved by bacterial effectors that target the small GTPases of the host. Modulation of microtubule dynamics involves direct interaction of effector proteins with the subunits of microtubules or recruiting cellular proteins that affect microtubule dynamics. This review will discuss effector proteins from animal and human bacterial pathogens that either destabilize or stabilize host micro-tubules to advance the infectious process. A compilation of these research findings will provide an overview of known and unknown strategies used by various bacterial effectors to modulate the host microtubule dynamics. The present review will undoubtedly help direct future research to determine the mechanisms of action of many bacterial effector proteins and contribute to understanding the survival strategies of diverse adherent and invasive bacterial pathogens.

Keywords

bacteria; bacterial effector proteins; cytoskeleton; microtubules

Introduction

The cytoskeleton is a cytoplasmic scaffold that determines cell shape, enables cell movement, and plays an essential role in intracellular organelle transport and cell division. The cytoskeleton network consists of three types of protein filaments: actin filaments, intermediate filaments, and microtubules. The eukaryotic cytoskeleton is targeted by a variety of bacterial and viral pathogens during the course of infection, and dynamic changes of the cytoskeleton influence the interaction of microbial pathogens with the host cells. Consequently, successful microbial pathogens modulate cytoskeleton dynamics to facilitate adherence to the cells, invasion, intra- and intercellular trafficking, and to prevent intracellular killing (1–6). Microbial pathogens deliver a number of effector proteins to the host cells to rearrange the cytoskeleton to benefit the infection process. These effector proteins essentially target small GTPases to modulate the dynamics of the actin cytoskeleton of host cells (3, 7–11). Rearrangement of the actin cytoskeleton by pathogenic microorganisms has been extensively reviewed elsewhere (3, 8, 10, 12–19). This review will focus on modulation of host microtubule dynamics by pathogenic bacteria.

*Corresponding author: Splitter@svm.vetmed.wisc.edu.

Microtubules are essential components of the eukaryotic cytoskeleton composed of heterodimers of α - and β -tubulin. Tubulin dimers polymerize to form a microtubule that consists of 13 linear protofilaments assembled around a hollow core (20, 21). Microtubules are polar structures with a fast-growing plus end and a slow-growing minus end, and this polarity determines the direction of movement along micro-tubules (22, 23). Important to cell function, microtubules are dynamic structures that undergo continual assembly and disassembly within the cell (24, 25). Many bacterial pathogens modulate this microtubule dynamics by employing virulence proteins to promote infection (Table 1). This review will discuss various bacterial effectors that destabilize or stabilize host microtubule networks.

Destabilization of host microtubule cytoskeleton by bacterial pathogens

Destabilization of host microtubules is a common strategy adopted by various bacterial pathogens (Figure 1). Microtubule destabilization benefits these pathogens in many ways, including the free movement of pathogens through the cytoplasm and modulation of actin cytoskeleton through the activation of small GTPases. Rearrangement of the actin cytoskeleton facilitates formation of membrane ruffles and pseudopodia that promotes bacterial invasion and movement. Examples of major bacterial effectors that destabilize micro-tubule networks are discussed below.

VirA of *Shigella*

Shigella flexneri, the causative agent of bacterial dysentery, harbors an important virulence gene, *VirA*, that encodes a 45-kDa protein (26). *Shigella* delivers *VirA* into the host cells using its type III secretion system (T3SS), and intracellular *VirA* modulates the cytoskeleton dynamics to facilitate bacterial entry and intracellular movement (27, 28). *Shigella* spp. deficient in the *VirA* gene are defective in intracellular movement and present an attenuated phenotype in a mouse model of infection (29). Studies have established that the *VirA* effector protein modulates host microtubule dynamics by acting as a destabilization factor (29). *Shigella* destroys the microtubule network in the infected cells and creates a tunnel through which the bacteria move smoothly. Infection studies using mutant bacteria indicated that these properties are attributed to the *VirA* protein of *Shigella*.

VirA interacts with the subunits of the microtubule through an N-terminal domain that is located between amino acid residues 224 and 315 (28). *VirA* can efficiently inhibit microtubule polymerization and induce depolymerization of assembled microtubules in a dose-dependent manner (28). However, the mechanism whereby *VirA* induces microtubule destabilization remained controversial. More recently, *VirA* was reported as a cysteine protease that specifically targets the α -subunit of the tubulin heterodimer (29). *VirA* is capable of degrading purified human α -tubulin, and the protease activity is sensitive to the protease inhibitors leupeptin and cystatin C. Mutation studies identified the catalytic cysteine residue at the N-terminus of *VirA* (C34), and its mutation to serine (*VirAC34S*) affects the activity of the protein (29). *VirAC34S* does not exhibit micro-tubule disruption in COS-7 cells, and *Shigella* expressing the respective mutant presented a defective intracellular movement (29). However, experimental data from two independent structural and functional studies contradicted the identified *VirA* mechanism of action (30, 31). The elucidated crystal structure of *VirA* reveals that it harbors two independently folded domains that resemble the letter 'V' (30, 31). *VirA* represents a novel protein fold and does not show any significant structural homology to papain-like cysteine proteases as indicated by previous biochemical assays. However, the N-terminal domain of *VirA* exhibits limited similarity to the inhibitors of cysteine proteases. The putative active site of *VirA* that contains the catalytic residue Cys34 appears disordered in the crystal structure. Structural analysis also pointed out that the N-terminal domain comprising the 224–315 amino acid region of *VirA* is very likely involved in dimer formation rather than tubulin interaction (30,

31). Nevertheless, there are conflicting reports on the existence of VirA as a monomer or dimer. In contrast to the previous report (29), others could not identify any obvious proteolytic activity or microtubule depolymerization properties by purified VirA protein (30, 31). VirA may act as a scaffold for a host papain-like cysteine protease, or recruits an unidentified microtubule-destabilizing protein to facilitate the microtubule destruction.

In addition to creating a tunnel for bacterial movement by destroying microtubule networks, VirA has the ability to induce membrane ruffles in various mammalian cells. VirA-induced membrane ruffles are reported to be mediated by the activation of the small GTPase Rac1. It has been hypothesized that microtubule regrowth after its depolymerization may activate Rac1, resulting in the development of membrane ruffles and lamellipodial protrusions that promote bacterial entry into host cells (28).

EspG of *Escherichia coli*

Enteropathogenic *E. coli* (EPEC) is a bacterial pathogen that causes gastroenteritis in humans (32). EPEC adheres to the gastrointestinal mucosa and forms attaching and effacing lesions that are characterized by localized destruction of the gastric microvillus brush border, intimate adherence of bacteria to epithelial cells, and cytoskeleton reorganization (32–34). EPEC injects a battery of effector proteins into intestinal epithelial cells through its T3SS to subvert the host cell processes to benefit the extracellular bacterium (33, 35). EPEC secretes effector proteins, EspG and EspG2, to destabilize microtubules. Importantly, EspG and EspG2 share a striking similarity (40% and 38%, respectively) to the VirA protein of *Shigella*, which is also a microtubule-destabilizing protein (36). There is a 62% similarity between EspG and EspG2 (36). Interestingly, *E. coli* EspG as well as EspG2 can restore the intracellular persistence of the *Shigella* VirA mutant, indicating a functional level similarity of EspG/EspG2 and VirA (36). *In vitro* infection studies using EspG mutant EPEC did not indicate any observable attenuated phenotype, whereas *in vivo* studies using a rabbit model of diarrhea presented with attenuated gut colonization by an EspG mutant (36).

Wild-type EPEC caused localized microtubule destruction beneath the site of adherence (37). Infection studies using mutant EPEC demonstrate that microtubule depletion is attributed to the *EspG* and *EspG2* or *orf3* genes. However, a single mutant of *EspG* did not exhibit microtubule destruction due to the functional redundancy of EspG and EspG2, whereas a double mutant was defective in microtubule depletion (37). Both EspG and EspG2 are capable of binding tubulins but not Taxol-stabilized microtubules (38). *In vitro* studies also demonstrate that EspG and EspG2 can efficiently inhibit microtubule polymerization as well as trigger the destabilization of polymerized microtubules (38). The exact mechanism of EspG/EspG2-mediated microtubule destruction remains unknown. Given the high similarity of VirA and EspG/EspG2, a cysteine protease activity has been proposed as the mechanism of microtubule destruction by EspG/EspG2. However, the protease activity of EspG/EspG2 has not been demonstrated. An alternative hypothesis suggests that EspG/EspG2 acts similarly to the microtubule-destabilizing protein, stathmin, which sequesters tubulins and reduces the concentration of tubulin available for microtubule assembly (38–40).

Escherichia coli is an extracellular bacterium, and how EspG/EspG2-induced microtubule destruction may benefit the pathogen remains largely unknown. EspG/EspG2-induced microtubule destruction triggers the release and activation of a microtubule-associated RhoA-specific guanine nucleotide exchange factor, GEF-H1. Activated GEF-H1 in turn activates a RhoA-ROCK signaling pathway and induces actin stress fiber formation (38). GEF-H1 associates with the epithelial tight junctions and regulates the paracellular permeability by reorganizing the actin cytoskeleton (41). Therefore, it is assumed that the

microtubule destruction by EspG/EspG2 leads to actin rearrangements and increased paracellular permeability, which contributes to EPEC-induced diarrhea.

EspG of *Citrobacter*

Citrobacter rodentium is a murine attaching and effacing pathogen that causes mild diarrhea and colonic hyperplasia in mice (42). EspG encoded by *C. rodentium* shares strong homology with the EspG of EPEC (43, 44). EspG, secreted by T3SS, of *C. rodentium* also binds to human tubulin and induces localized microtubule destruction and stimulates actin stress fiber formation (45). Disrupting microtubules in colonocytes by EspG and potentially with EspF, the various cell membrane aquaporin water channels that normally absorb water from the gut are repositioned to the cell cytoplasm, contributing to diarrhea during bacterial infection (46).

CopN of *Chlamydia*

The Chlamydiae are Gram-negative, obligate intracellular pathogens that cause a range of human diseases, including genital, ocular, and respiratory infections (47). They undergo a biphasic developmental cycle involving the infectious elementary body (EB), and the replicative, non-infectious reticulate body (RB) (48). After entering their target eukaryotic cells, EBs differentiate into RBs and replicate within an endosome-derived membranous vacuole, termed 'inclusion' (48). Microtubules play an essential role in the intracellular lifestyle of *Chlamydia*. Chlamydial inclusions are trafficked along microtubules toward the minus ends and aggregate at the microtubule organizing center (MTOC) (49, 50). Disruption of microtubules by nocodazole treatment in Cos-7 cells inhibited the characteristic localization of *Chlamydia* inclusions. Studies have shown that inclusion body translocation depends on the minus-end-directed microtubule motor complex dyenin (49).

Even though *Chlamydia* exploits the microtubule network for trafficking of inclusions, one of the *Chlamydia* effectors, CopN, exhibits microtubule destabilization properties (51). Heterologous expression of CopN in yeast and mammalian cells affected the formation of microtubule structures and blocks cell division (52). Recently, CopN was shown to directly bind non-polymerized α and β -tubulins but not to polymerized microtubules (53). CopN can efficiently inhibit microtubule polymerization but cannot induce depolymerization due to its inability to bind to the polymerized microtubules. On the basis of these observations, it is hypothesized that CopN may act like stathmin and destabilize the microtubules by sequestering α - and β -tubulins (53). *Chlamydia* resides at the MTOC, and the microtubule destabilization property of CopN may disrupt the mitotic spindles, leading to chromosomal segregation defects and inhibition of cytokinesis.

EseG of *Edwardsiella tarda*

Edwardsiella tarda is an enteric pathogen that causes septicemia of fish and gastroenteritis of humans (54). *Edwardsiella tarda* secretes an effector protein, EseG, to the host cells through a T3SS. Overexpression of EseG in HeLa cells induces dramatic microtubule destruction (55). EseG does not share any homology with other microtubule-destabilizing proteins such as VirA and EspG. However, EseG does share a conserved domain with the SseF and SseG proteins of *Salmonella*. A microtubule destabilization property has not been demonstrated for SseF or SseG, and these effector proteins play an essential role in the perinuclear localization of *Salmonella*-containing vacuoles. In fact, SseG co-localizes with microtubules and exhibit microtubule-bundling properties (56). Nevertheless, the conserved domain is reported to be essential for EseG to destabilize microtubules (55). EseG interacts with α -tubulin through a separate domain at the N-terminus of the protein (55). The actual mechanism of EseG-mediated microtubule destruction remains to be elucidated.

ActA of *Listeria*

Listeria monocytogenes is an intracellular pathogenic bacterium that causes the severe food-borne infection listeriosis (57). *Listeria* is capable of invading and replicating in a variety of mammalian cells. After internalization, *Listeria* prevents phagosome-lysosome fusion and escapes from the phagosome with the help of its virulence protein, LLO (58). Free bacteria then replicate in the cells and spread to neighboring cells without inducing cell lysis (58–60). *Listeria* encodes a number of virulence factors to facilitate its intra-cellular survival and spread (61). Studies have shown that ActA is essential for inter- and intracellular movement of *Listeria*. ActA induces a comet-shaped actin polymerization at the posterior pole of the bacterium that generates unidirectional propulsion force to push the bacterium through the cytoplasm. ActA mimics the C-terminal domain of Wiskott-Aldrich syndrome protein (WASP) and activates actin-related protein (Arp) 2/3 complex to facilitate the comet formation at the pole of the bacterium (62). The microtubule-binding protein dynamin-2 co-localizes with the *Listeria*-induced actin comets. Dynamin-2 is a GTPase protein that is ubiquitously expressed in mammals and plays key roles in various cellular processes, including fission of clathrin-coated endocytic vesicles, vesicle trafficking, centrosome cohesion, actin reorganization, and microtubule dynamics (63–67). Dynamin-2 polymerizes the entire length around the microtubules and contributes to the correct bundling of microtubules. Silencing of dynamin-2 by siRNA results in dynamic instability of microtubules and induces accumulation of acetylated and stable microtubules (68). Infection of dynamin-2-depleted HeLa cells with *Listeria* reduces actin comet tail formation and diminishes the speed of bacterial movement (69). These studies imply that the alteration of microtubule dynamics influences the *Listeria*-induced actin comet tail formation. A number of actin regulatory proteins such as Rho family GTPases are associated with microtubules, and microtubule dynamics regulate actin regulatory protein release and activation (70–72). Therefore, alterations of microtubule dynamics likely affect the reorganization of actin cytoskeleton and the formation of actin comets.

A high-throughput yeast two-hybrid screen identified a mammalian protein, LaXp180, that interacts with ActA of *Listeria* (73). LaXp180 interacts with a well-characterized microtubule-destabilizing protein, stathmin (74). Stathmin sequesters tubulin dimers by forming a complex and reduces the concentration of free tubulin available for polymerization (39, 40, 75). In addition to the tubulin sequestration, stathmin also promotes microtubule catastrophe or shortening through an unidentified mechanism (75). The role of microtubules on the intracellular lifestyle of *Listeria* has not been investigated in detail. However, stathmin-mediated microtubule depletion by *Listeria* proteins may lead to actin rearrangement that promotes bacterial movement and spread. Studies have shown that the microtubule destabilization property of stathmin is inactivated by its phosphorylation, and the phosphorylated stathmin induces lamellipodia formation that is mediated by a multiprotein complex termed WAVE-2 (76, 77). Whether the ActA-LaXp180-stathmin interaction induces lamellipodia formation to promote the spread of *Listeria* is an area that needs to be addressed.

Stabilization of host microtubule cytoskeleton by bacterial pathogens

Many invasive and adherent bacterial pathogens induce stabilization of host microtubules to promote their survival and persistence (Figure 2). The mechanism by which bacterial effector proteins induce the stabilization of host microtubules and the beneficial role of stabilized microtubules for survival of certain pathogens in the host are poorly understood. Major bacterial effector proteins that stabilize host microtubules are as follows.

SifA of *Salmonella*

Salmonellae are gastrointestinal pathogens causing diseases ranging from enteritis to typhoid fever (78). They are facultative intracellular pathogens and reside in membranous compartments termed *Salmonella*-containing vacuoles (SCV). *Salmonella* possess two T3SS to deliver its effector proteins to the host cytosol to modify the host cell processes to benefit the pathogen. The *Salmonella*-secreted proteins SifA, SseF, and SseG have been reported to affect micro-tubule dynamics (56). SifA is an important virulence protein of *Salmonella* and induces tubular networks, termed as *Salmonella*-induced filaments (SIFs), that extend from the SCVs (79). SIF formation is essential for pathogenicity as the SifA mutant *Salmonella* presents an attenuated phenotype in mice and macrophages (80, 81). Intact microtubules are required for the formation of SIFs, indicating that SIF structures are formed on the scaffolding of microtubules (56, 79). Recent studies have shown that SIFs constitute the tubular aggregates of phagosomes, and the tubular networks require the participation of host SifA kinesin-interacting protein, SKIP, and the microtubule motor, kinesin-1 (82, 83). The *Salmonella* effectors SseG and SseF interfere with microtubule organization and induce massive microtubule bundling (56). It is hypothesized that microtubule reorganization may reduce or block the vesicles that transport along the microtubules. Therefore, microtubule bundling may bring the vesicles in close proximity, leading to their fusion and formation of tubular networks along the microtubules (56) benefiting the *Salmonella*. The mechanism by which these *Salmonella* effectors alter the microtubule organization remains obscure.

TcpB of *Brucella* spp

Brucella spp. are infectious intracellular pathogens causing brucellosis of animals and humans (84). *Brucella* spp. encode a Toll/interleukin-like receptor domain (TIR domain)-containing protein termed TcpB/Bpt1. TcpB harbors a phosphoinositide-binding domain at the N-terminus and a TIR domain at the C-terminus (85). TcpB inhibits host innate immune responses mediated by TLR2 and TLR4 (85–87). Recent studies have shown that TcpB targets a TLR adaptor protein, TIRAP, to inhibit TLRs by inducing the ubiquitination and degradation of TIRAP (85, 88). Overexpression of TcpB in mammalian cells resulted in dramatic cell shrinkage and rounding up, suggesting a potential interaction with microtubules of the cell. Subcellular localization studies indicate that TcpB co-localizes predominantly with the microtubules (Figure 3) (85). Microtubule localization is attributed to the TIR domain of TcpB and a point mutation at the active site of TIR domain, i.e., BB-loop, abolished the affinity for microtubules. TcpB-expressing cells display thickened and bundled microtubule networks indicative of microtubule stabilization.

Polymerization of microtubules in the presence of purified TcpB reveals a robust microtubule stabilization property of TcpB. TcpB acts like the microtubule-stabilizing drug paclitaxel, and dramatically enhances the nucleation and growth phases of microtubule polymerization (Figure 4) (89). In addition, TcpB can efficiently suppress the inhibition of microtubule depolymerization by nocodazole or cold. In agreement with the subcellular localization studies, a BB-loop mutant TcpB exhibits defective microtubule binding and stabilization properties (89).

The significance of TcpB-microtubule interaction and microtubule stabilization remains obscure. Potentially, TcpB induces microtubule bundling to interfere with the vesicular transport along microtubule tracks that may benefit *Brucellae* to prevent phagosome-lysosome fusion and subsequent phagosomal killing. However, experiments to demonstrate the secretion of TcpB by *Brucella* have not yet been successful. As the intact BB-loop is crucial for both microtubule stabilization as well as TLR inhibition, a correlation between these two properties has also been hypothesized. Nevertheless, the role of microtubules in

the regulation of TLR signaling remains enigmatic. Studies are in progress to address the significance and mechanism of TcpB-induced microtubule stabilization.

CDT toxin of *Clostridium difficile*

Clostridium difficile is a major cause of chronic antibiotic-associated diarrhea and pseudomembranous colitis (90). Hypervirulent strains of *C. difficile* produce the binary actin-ADP ribosylating toxin, *C. difficile* transferase (CDT). CDT depolymerizes the actin cytoskeleton using its actin-modifying ADP-ribosyltransferase property. Expression of CDT in the human colon carcinoma cell line Caco-2 induced characteristic cell surface projections that consist of microtubules (91). Subsequent analyses indicate that in the presence of CDT, microtubules form bundles and grow along the cell cortex and project from the cell surface. The microtubules that cross the cell borders are capped with a microtubule plus-end-tracking protein, EB1, indicating that microtubule protrusions are the result of tubulin polymerization rather than sliding of microtubules. In addition, CDT causes redistribution of microtubule-capturing proteins, CLASP2 and ACF7, from the cell periphery to the cell interior (91). The capture of growing microtubules at the cell cortex by tip-associated proteins is an important process that regulates microtubule dynamics (92, 93). Interfering with this capturing process by CDT may contribute to the growth of microtubules beyond the cell borders. Induction of microtubule-derived cell protrusions increase adherence and colonization of *Clostridia* on epithelial cells (91). The iota toxin of *Clostridium perfringens* and C2 toxin of *Clostridium botulinum* also induce microtubule-based protrusions on the surface of epithelial cells (91).

Pneumolysin of *Streptococcus pneumoniae*

Streptococcus pneumoniae is a major causative agent of bacterial meningitis (94). *Streptococcus pneumoniae* encodes pneumolysin (Ply), a member of the cholesterol-dependent cytolysins that is essential for the virulence of the bacteria (95, 96). Microtubule stabilization is observed in pneumococcal meningitis and is attributed to the pneumolysin of *S. pneumoniae* (97). The expression of sublytic levels of pneumolysin in SH-SY5Y neuron cells induces massive microtubule bundling and increased levels of acetylated tubulin and stabilized microtubules (97). Ply-induced microtubule bundling is partially affected by the addition of Src-kinase family inhibitors. As members of the tyrosine kinase family are known to promote tubulin polymerization and stabilize microtubules, Ply-mediated microtubule stabilization is thought to be mediated by tyrosine kinases (97–99). Ply-mediated microtubule stability and bundling inhibits organelle transport as demonstrated for defective mitochondrial transport in Chinese hamster ovary cells (97). Therefore, defective organelle transport caused by microtubule stabilization may explain the neuronal dysfunction in the course of pneumococcal meningitis. *Streptococcus pneumoniae* is not a classic intracellular pathogen; however, it is capable of invading and propagating in host cells (100, 101). Therefore, Ply-induced microtubule stabilization may help the intracellular survival of the bacterium by interfering with the vesicular transport and inhibiting phagosome killing.

Despite extensive research in the field of host-pathogen interaction, the mechanism of action of many of the above-discussed effector proteins remains to be elucidated. Therefore, future studies need to address various effector protein strategies that modulate the host microtubule dynamics and its contribution to the survival and persistence of bacterial pathogens in the host. Insights into the effector protein-micro-tubule interaction will undoubtedly provide an opportunity to develop innovative therapeutic strategies, such as antivirulence drugs that inhibit the specific functions of the effector protein. Future research should also focus on identifying novel virulence proteins of pathogenic microorganisms that target the organization of host microtubule networks.

Conclusion

Microtubules are easy targets of pathogenic microorganisms for hijacking the cellular processes to create a replication-permissive niche. Modulation of microtubule dynamics benefits the pathogen in various ways, including promoting intracellular motility, interfering with vesicular trafficking, and reorganizing the actin cytoskeleton. Therefore, detailed studies on microtubule-pathogen interaction will undoubtedly contribute to our understanding of pathogenicity and host adaptation of several infectious pathogens. Additionally, the virulence proteins that affect microtubule dynamics constitute a handy tool for dissecting various cellular processes that are regulated by microtubules. Similar studies will also provide valuable insight into the influence of microtubules on the dynamics of the actin cytoskeleton.

Acknowledgments

This work was supported by the National Institutes of Health (grant nos. R03AI101611 and R01 AIO73558) and the Binational Agricultural Research and Development (BARD) Fund (grant no. US-4378-11).

References

1. Roberts KL, Baines JD. Actin in herpesvirus infection. *Viruses*. 2011; 3:336–46. [PubMed: 21994736]
2. Yoshida S, Sasakawa C. Exploiting host microtubule dynamics: a new aspect of bacterial invasion. *Trends Microbiol*. 2003; 11:139–43. [PubMed: 12648946]
3. Aktories K. Bacterial protein toxins that modify host regulatory GTPases. *Nat Rev Microbiol*. 2011; 9:487–98. [PubMed: 21677684]
4. Goosney DL, Knoechel DG, Finlay BB. Enteropathogenic *E. coli*, *Salmonella*, and *Shigella*: masters of host cell cytoskeletal exploitation. *Emerg Infect Dis*. 1999; 5:216–23. [PubMed: 10221873]
5. Stebbins CE. Structural insights into bacterial modulation of the host cytoskeleton. *Curr Opin Struct Biol*. 2004; 14:731–40. [PubMed: 15582397]
6. Stolp B, Fackler OT. How HIV takes advantage of the cytoskeleton in entry and replication. *Viruses*. 2011; 3:293–311. [PubMed: 21994733]
7. Campellone KG. Cytoskeleton-modulating effectors of enteropathogenic and enterohaemorrhagic *Escherichia coli*: Tir, EspFU and actin pedestal assembly. *FEBS J*. 2010; 277:2390–402. [PubMed: 20477869]
8. Aepfelbacher M, Zumbihl R, Heesemann J. Modulation of Rho GTPases and the actin cytoskeleton by YopT of *Yersinia*. *Curr Top Microbiol Immunol*. 2005; 291:167–75. [PubMed: 15981463]
9. Boquet P. Small GTP binding proteins and bacterial virulence. *Microbes Infect*. 2000; 2:837–43. [PubMed: 10955965]
10. Finlay BB. Bacterial virulence strategies that utilize Rho GTPases. *Curr Top Microbiol Immunol*. 2005; 291:1–10. [PubMed: 15981456]
11. Schlumberger MC, Hardt WD. Triggered phagocytosis by *Salmonella*: bacterial molecular mimicry of RhoGTPase activation/deactivation. *Curr Top Microbiol Immunol*. 2005; 291:29–42. [PubMed: 15981458]
12. Aktories K, Barbieri JT. Bacterial cytotoxins: targeting eukaryotic switches. *Nat Rev Microbiol*. 2005; 3:397–410. [PubMed: 15821726]
13. Aktories K. Rho proteins: targets for bacterial toxins. *Trends Microbiol*. 1997; 5:282–8. [PubMed: 9234511]
14. Aktories K, Lang AE, Schwan C, Mannherz HG. Actin as target for modification by bacterial protein toxins. *FEBS J*. 2011; 278:4526–43. [PubMed: 21466657]
15. Barbieri JT, Riese MJ, Aktories K. Bacterial toxins that modify the actin cytoskeleton. *Annu Rev Cell Dev Biol*. 2002; 18:315–44. [PubMed: 12142277]

16. Fiorentini C, Falzano L, Travaglione S, Fabbri A. Hijacking Rho GTPases by protein toxins and apoptosis: molecular strategies of pathogenic bacteria. *Cell Death Differ*. 2003; 10:147–52. [PubMed: 12700642]
17. Gruenheid S, Finlay BB. Microbial pathogenesis and cytoskeletal function. *Nature*. 2003; 422:775–81. [PubMed: 12700772]
18. Stevens JM, Galyov EE, Stevens MP. Actin-dependent movement of bacterial pathogens. *Nat Rev Microbiol*. 2006; 4:91–101. [PubMed: 16415925]
19. Le Clainche C, Drubin DG. Actin lessons from pathogens. *Mol Cell*. 2004; 13:453–4. [PubMed: 14992714]
20. Downing KH, Nogales E. Tubulin structure: insights into microtubule properties and functions. *Curr Opin Struct Biol*. 1998; 8:785–91. [PubMed: 9914260]
21. Nogales E. Structural insights into microtubule function. *Annu Rev Biochem*. 2000; 69:277–302. [PubMed: 10966460]
22. Mandelkow E, Mandelkow EM. Microtubular structure and tubulin polymerization. *Curr Opin Cell Biol*. 1989; 1:5–9. [PubMed: 2517019]
23. Hirokawa N. Kinesin and dynein superfamily proteins and the mechanism of organelle transport. *Science*. 1998; 279:519–26. [PubMed: 9438838]
24. Desai A, Mitchison TJ. Microtubule polymerization dynamics. *Annu Rev Cell Dev Biol*. 1997; 13:83–117. [PubMed: 9442869]
25. Howard J, Hyman AA. Dynamics and mechanics of the microtubule plus end. *Nature*. 2003; 422:753–8. [PubMed: 12700769]
26. Uchiya K, Tobe T, Komatsu K, Suzuki T, Watarai M, Fukuda I, Yoshikawa M, Sasakawa C. Identification of a novel virulence gene, *virA*, on the large plasmid of *Shigella*, involved in invasion and intercellular spreading. *Mol Microbiol*. 1995; 17:241–50. [PubMed: 7494473]
27. Demers B, Sansonetti PJ, Parsot C. Induction of type III secretion in *Shigella flexneri* is associated with differential control of transcription of genes encoding secreted proteins. *EMBO J*. 1998; 17:2894–903. [PubMed: 9582283]
28. Yoshida S, Katayama E, Kuwae A, Mimuro H, Suzuki T, Sasakawa C. *Shigella* deliver an effector protein to trigger host microtubule destabilization, which promotes Rac1 activity and efficient bacterial internalization. *EMBO J*. 2002; 21:2923–35. [PubMed: 12065406]
29. Yoshida S, Handa Y, Suzuki T, Ogawa M, Suzuki M, Tamai A, Abe A, Katayama E, Sasakawa C. Microtubule-severing activity of *Shigella* is pivotal for intercellular spreading. *Science*. 2006; 314:985–9. [PubMed: 17095701]
30. Davis J, Wang J, Tropea JE, Zhang D, Dauter Z, Waugh DS, Wlodawer A. Novel fold of *VirA*, a type III secretion system effector protein from *Shigella flexneri*. *Protein Sci*. 2008; 17:2167–73. [PubMed: 18787201]
31. Germane KL, Ohi R, Goldberg MB, Spiller BW. Structural and functional studies indicate that *Shigella* *VirA* is not a protease and does not directly destabilize microtubules. *Biochemistry*. 2008; 47:10241–3. [PubMed: 18763811]
32. Kaper JB, Nataro JP, Mobley HL. Pathogenic *Escherichia coli*. *Nat Rev Microbiol*. 2004; 2:123–40. [PubMed: 15040260]
33. Frankel G, Phillips AD, Rosenshine I, Dougan G, Kaper JB, Knutton S. Enteropathogenic and enterohaemorrhagic *Escherichia coli*: more subversive elements. *Mol Microbiol*. 1998; 30:911–21. [PubMed: 9988469]
34. Celli J, Deng W, Finlay BB. Enteropathogenic *Escherichia coli* (EPEC) attachment to epithelial cells: exploiting the host cell cytoskeleton from the outside. *Cell Microbiol*. 2000; 2:1–9. [PubMed: 11207558]
35. Garmendia J, Frankel G, Crepin VF. Enteropathogenic and enterohemorrhagic *Escherichia coli* infections: translocation, translocation, translocation. *Infect Immun*. 2005; 73:2573–85. [PubMed: 15845459]
36. Elliott SJ, Krejany EO, Mellies JL, Robins-Browne RM, Sasakawa C, Kaper JB. *EspG*, a novel type III system-secreted protein from enteropathogenic *Escherichia coli* with similarities to *VirA* of *Shigella flexneri*. *Infect Immun*. 2001; 69:4027–33. [PubMed: 11349072]

37. Shaw RK, Smollett K, Cleary J, Garmendia J, Straatman-Iwanowska A, Frankel G, Knutton S. Enteropathogenic *Escherichia coli* type III effectors EspG and EspG2 disrupt the microtubule network of intestinal epithelial cells. *Infect Immun*. 2005; 73:4385–90. [PubMed: 15972534]
38. Matsuzawa T, Kuwae A, Yoshida S, Sasakawa C, Abe A. Enteropathogenic *Escherichia coli* activates the RhoA signaling pathway via the stimulation of GEF-H1. *EMBO J*. 2004; 23:3570–82. [PubMed: 15318166]
39. Cassimeris L. The oncoprotein 18/stathmin family of microtubule destabilizers. *Curr Opin Cell Biol*. 2002; 14:18–24. [PubMed: 11792540]
40. Howell B, Larsson N, Gullberg M, Cassimeris L. Dissociation of the tubulin-sequestering and microtubule catastrophe-promoting activities of oncoprotein 18/stathmin. *Mol Biol Cell*. 1999; 10:105–18. [PubMed: 9880330]
41. Benais-Pont G, Punn A, Flores-Maldonado C, Eckert J, Raposo G, Fleming TP, Cerejido M, Balda MS, Matter K. Identification of a tight junction-associated guanine nucleotide exchange factor that activates Rho and regulates paracellular permeability. *J Cell Biol*. 2003; 160:729–40. [PubMed: 12604587]
42. Luperchio SA, Schauer DB. Molecular pathogenesis of *Citrobacter rodentium* and transmissible murine colonic hyperplasia. *Microbes Infect*. 2001; 3:333–40. [PubMed: 11334751]
43. Deng W, Li Y, Vallance BA, Finlay BB. Locus of enterocyte effacement from *Citrobacter rodentium*: sequence analysis and evidence for horizontal transfer among attaching and effacing pathogens. *Infect Immun*. 2001; 69:6323–35. [PubMed: 11553577]
44. Mundy R, Petrovska L, Smollett K, Simpson N, Wilson RK, Yu J, Tu X, Rosenshine I, Clare S, Dougan G, Frankel G. Identification of a novel *Citrobacter rodentium* type III secreted protein, EspI, and roles of this and other secreted proteins in infection. *Infect Immun*. 2004; 72:2288–302. [PubMed: 15039354]
45. Hardwidge PR, Deng W, Vallance BA, Rodriguez-Escudero I, Cid VJ, Molina M, Finlay BB. Modulation of host cytoskeleton function by the enteropathogenic *Escherichia coli* and *Citrobacter rodentium* effector protein EspG. *Infect Immun*. 2005; 73:2586–94. [PubMed: 15845460]
46. Guttman JA, Samji FN, Li Y, Deng W, Lin A, Finlay BB. Aquaporins contribute to diarrhoea caused by attaching and effacing bacterial pathogens. *Cell Microbiol*. 2007; 9:131–41. [PubMed: 16889624]
47. Schachter, J. Overview of human diseases. In: Barron, AL., editor. *Microbiology of Chlamydia*. Boca Raton, FL: CRC Press; 1988. p. 153–65.
48. Moulder JW. Interaction of chlamydiae and host cells in vitro. *Microbiol Rev*. 1991; 55:143–90. [PubMed: 2030670]
49. Grieshaber SS, Grieshaber NA, Hackstadt T. *Chlamydia trachomatis* uses host cell dynein to traffic to the microtubule-organizing center in a p50 dynamitin-independent process. *J Cell Sci*. 2003; 116(Pt 18):3793–802. [PubMed: 12902405]
50. Scidmore MA. Recent advances in *Chlamydia* subversion of host cytoskeletal and membrane trafficking pathways. *Microbes Infect*. 2011; 13:527–35. [PubMed: 21334451]
51. Alzhanov DT, Weeks SK, Burnett JR, Rockey DD. Cytokinesis is blocked in mammalian cells transfected with *Chlamydia trachomatis* gene CT223. *BMC Microbiol*. 2009; 9:2. [PubMed: 19123944]
52. Huang J, Lesser CF, Lory S. The essential role of the CopN protein in *Chlamydia pneumoniae* intracellular growth. *Nature*. 2008; 456:112–5. [PubMed: 18830244]
53. Archuleta TL, Du Y, English CA, Lory S, Lesser C, Ohi MD, Ohi R, Spiller BW. The *Chlamydia* effector chlamydial outer protein N (CopN) sequesters tubulin and prevents microtubule assembly. *J Biol Chem*. 2011; 286:33992–8. [PubMed: 21841198]
54. Leung KY, Siame BA, Tenkink BJ, Noort RJ, Mok YK. *Edwardsiella tarda* – virulence mechanisms of an emerging gastroenteritis pathogen. *Microbes Infect*. 2012; 14:26–34. [PubMed: 21924375]
55. Xie HX, Yu HB, Zheng J, Nie P, Foster LJ, Mok YK, Finlay BB, Leung KY. EseG, an effector of the type III secretion system of *Edwardsiella tarda*, triggers microtubule destabilization. *Infect Immun*. 2010; 78:5011–21. [PubMed: 20855515]

56. Kuhle V, Jackel D, Hensel M. Effector proteins encoded by *Salmonella* pathogenicity island 2 interfere with the microtubule cytoskeleton after translocation into host cells. *Traffic*. 2004; 5:356–70. [PubMed: 15086785]
57. Swaminathan B, Gerner-Smidt P. The epidemiology of human listeriosis. *Microbes Infect*. 2007; 9:1236–43. [PubMed: 17720602]
58. Dussurget O. New insights into determinants of *Listeria monocytogenes* virulence. *Int Rev Cell Mol Biol*. 2008; 270:1–38. [PubMed: 19081533]
59. Ray K, Marteyn B, Sansonetti PJ, Tang CM. Life on the inside: the intracellular lifestyle of cytosolic bacteria. *Nat Rev Microbiol*. 2009; 7:333–40. [PubMed: 19369949]
60. Stavru F, Archambaud C, Cossart P. Cell biology and immunology of *Listeria monocytogenes* infections: novel insights. *Immunol Rev*. 2011; 240:160–84. [PubMed: 21349093]
61. Kuhn M, Goebel W. Molecular studies on the virulence of *Listeria monocytogenes*. *Genet Eng (NY)*. 1995; 17:31–51.
62. Zalevsky J, Grigorova I, Mullins RD. Activation of the Arp2/3 complex by the *Listeria acta* protein. Acta binds two actin monomers and three subunits of the Arp2/3 complex. *J Biol Chem*. 2001; 276:3468–75. [PubMed: 11029465]
63. Lee E, De Camilli P. Dynamin at actin tails. *Proc Natl Acad Sci USA*. 2002; 99:161–6. [PubMed: 11782545]
64. Praefcke GJ, McMahon HT. The dynamin superfamily: universal membrane tubulation and fission molecules? *Nat Rev Mol Cell Biol*. 2004; 5:133–47. [PubMed: 15040446]
65. Schafer DA. Regulating actin dynamics at membranes: a focus on dynamin. *Traffic*. 2004; 5:463–9. [PubMed: 15180823]
66. Takei K, McPherson PS, Schmid SL, De Camilli P. Tubular membrane invaginations coated by dynamin rings are induced by GTP- γ S in nerve terminals. *Nature*. 1995; 374:186–90. [PubMed: 7877693]
67. Thompson HM, Cao H, Chen J, Euteneuer U, McNiven MA. Dynamin 2 binds γ -tubulin and participates in centrosome cohesion. *Nat Cell Biol*. 2004; 6:335–42. [PubMed: 15048127]
68. Tanabe K, Takei K. Dynamic instability of microtubules requires dynamin 2 and is impaired in a Charcot-Marie-Tooth mutant. *J Cell Biol*. 2009; 185:939–48. [PubMed: 19528294]
69. Henmi Y, Tanabe K, Takei K. Disruption of microtubule network rescues aberrant actin comets in dynamin2-depleted cells. *PLoS One*. 2011; 6:e28603. [PubMed: 22174845]
70. Wittmann T, Waterman-Storer CM. Cell motility: can Rho GTPases and microtubules point the way? *J Cell Sci*. 2001; 114(Pt 21):3795–803. [PubMed: 11719546]
71. Liu BP, Chrzanowska-Wodnicka M, Burridge K. Microtubule depolymerization induces stress fibers, focal adhesions, and DNA synthesis via the GTP-binding protein Rho. *Cell Adhes Commun*. 1998; 5:249–55. [PubMed: 9762466]
72. Ren XD, Kiosses WB, Schwartz MA. Regulation of the small GTP-binding protein Rho by cell adhesion and the cytoskeleton. *EMBO J*. 1999; 18:578–85. [PubMed: 9927417]
73. Pfeuffer T, Goebel W, Laubinger J, Bachmann M, Kuhn M. LaXp180, a mammalian ActA-binding protein, identified with the yeast two-hybrid system, co-localizes with intracellular *Listeria monocytogenes*. *Cell Microbiol*. 2000; 2:101–14. [PubMed: 11207567]
74. Maucuer A, Camonis JH, Sobel A. Stathmin interaction with a putative kinase and coiled-coil-forming protein domains. *Proc Natl Acad Sci USA*. 1995; 92:3100–4. [PubMed: 7724523]
75. Belmont LD, Mitchison TJ. Identification of a protein that interacts with tubulin dimers and increases the catastrophe rate of microtubules. *Cell*. 1996; 84:623–31. [PubMed: 8598048]
76. Oikawa T, Yamaguchi H, Itoh T, Kato M, Ijuin T, Yamazaki D, Suetsugu S, Takenawa T. PtdIns(3,4,5)P3 binding is necessary for WAVE2-induced formation of lamellipodia. *Nat Cell Biol*. 2004; 6:420–6. [PubMed: 15107862]
77. Takahashi K. WAVE2 protein complex coupled to membrane and microtubules. *J Oncol*. 2012; 2012:590531. [PubMed: 22315597]
78. Ohl ME, Miller SI. *Salmonella*: a model for bacterial pathogenesis. *Annu Rev Med*. 2001; 52:259–74. [PubMed: 11160778]

79. Brumell JH, Goosney DL, Finlay BB. SifA, a type III secreted effector of *Salmonella typhimurium*, directs *Salmonella*-induced filament (Sif) formation along microtubules. *Traffic*. 2002; 3:407–15. [PubMed: 12010459]
80. Beuzon CR, Meresse S, Unsworth KE, Ruiz-Albert J, Garvis S, Waterman SR, Ryder TA, Boucrot E, Holden DW. *Salmonella* maintains the integrity of its intracellular vacuole through the action of SifA. *EMBO J*. 2000; 19:3235–49. [PubMed: 10880437]
81. Stein MA, Leung KY, Zwick M, Garcia-del Portillo F, Finlay BB. Identification of a *Salmonella* virulence gene required for formation of filamentous structures containing lysosomal membrane glycoproteins within epithelial cells. *Mol Microbiol*. 1996; 20:151–64. [PubMed: 8861213]
82. Schroeder N, Mota LJ, Meresse S. *Salmonella*-induced tubular networks. *Trends Microbiol*. 2011; 19:268–77. [PubMed: 21353564]
83. Ohlson MB, Huang Z, Alto NM, Blanc MP, Dixon JE, Chai J, Miller SI. Structure and function of *Salmonella* SifA indicate that its interactions with SKIP, SseJ, and RhoA family GTPases induce endosomal tubulation. *Cell Host Microbe*. 2008; 4:434–46. [PubMed: 18996344]
84. Pappas G, Akritidis N, Bosilkovski M, Tsianos E. Brucellosis. *N Engl J Med*. 2005; 352:2325–36. [PubMed: 15930423]
85. Radhakrishnan GK, Yu Q, Harms JS, Splitter GA. Brucella TIR domain-containing protein mimics properties of the toll-like receptor adaptor protein TIRAP. *J Biol Chem*. 2009; 284:9892–8. [PubMed: 19196716]
86. Cirli C, Wieser A, Yadav M, Duerr S, Schubert S, Fischer H, Stappert D, Wantia N, Rodriguez N, Wagner H, Svanborg C, Miethke T. Subversion of Toll-like receptor signaling by a unique family of bacterial Toll/interleukin-1 receptor domain-containing proteins. *Nat Med*. 2008; 14:399–406. [PubMed: 18327267]
87. Newman RM, Salunkhe P, Godzik A, Reed JC. Identification and characterization of a novel bacterial virulence factor that shares homology with mammalian Toll/interleukin-1 receptor family proteins. *Infect Immun*. 2006; 74:594–601. [PubMed: 16369016]
88. Sengupta D, Koblansky A, Gaines J, Brown T, West AP, Zhang D, Nishikawa T, Park SG, Roop RM 2nd, Ghosh S. Subversion of innate immune responses by *Brucella* through the targeted degradation of the TLR signaling adapter, MAL. *J Immunol*. 2010; 184:956–64. [PubMed: 20018612]
89. Radhakrishnan GK, Harms JS, Splitter GA. Modulation of microtubule dynamics by a TIR domain protein from the intra-cellular pathogen *Brucella melitensis*. *Biochem J*. 2011; 439:79–83. [PubMed: 21692747]
90. Kelly CP, LaMont JT. *Clostridium difficile* – more difficult than ever. *N Engl J Med*. 2008; 359:1932–40. [PubMed: 18971494]
91. Schwan C, Stecher B, Tzivelekidis T, van Ham M, Rohde M, Hardt WD, Wehland J, Aktories K. *Clostridium difficile* toxin CDT induces formation of microtubule-based protrusions and increases adherence of bacteria. *PLoS Pathog*. 2009; 5:e1000626. [PubMed: 19834554]
92. Mimori-Kiyosue Y, Grigoriev I, Lansbergen G, Sasaki H, Matsui C, Severin F, Galjart N, Grosveld F, Vorobjev I, Tsukita S, Akhmanova A. CLASP1 and CLASP2 bind to EB1 and regulate microtubule plus-end dynamics at the cell cortex. *J Cell Biol*. 2005; 168:141–53. [PubMed: 15631994]
93. Akhmanova A, Hoogenraad CC, Drabek K, Stepanova T, Dortland B, Verkerk T, Vermeulen W, Burgering BM, De Zeeuw CI, Grosveld F, Galjart N. Clasps are CLIP-115 and -170 associating proteins involved in the regional regulation of microtubule dynamics in motile fibroblasts. *Cell*. 2001; 104:923–35. [PubMed: 11290329]
94. Durand ML, Calderwood SB, Weber DJ, Miller SI, Southwick FS, Caviness VS Jr, Swartz MN. Acute bacterial meningitis in adults. A review of 493 episodes. *N Engl J Med*. 1993; 328:21–8. [PubMed: 8416268]
95. Orihuela CJ, Gao G, Francis KP, Yu J, Tuomanen EI. Tissue-specific contributions of pneumococcal virulence factors to pathogenesis. *J Infect Dis*. 2004; 190:1661–9. [PubMed: 15478073]

96. Hirst RA, Gosai B, Rutman A, Guerin CJ, Nicotera P, Andrew PW, O'Callaghan C. Streptococcus pneumoniae deficient in pneumolysin or autolysin has reduced virulence in meningitis. *J Infect Dis.* 2008; 197:744–51. [PubMed: 18260758]
97. Iliev AI, Djannatian JR, Opazo F, Gerber J, Nau R, Mitchell TJ, Wouters FS. Rapid microtubule bundling and stabilization by the Streptococcus pneumoniae neurotoxin pneumolysin in a cholesterol-dependent, non-lytic and Src-kinase dependent manner inhibits intracellular trafficking. *Mol Microbiol.* 2009; 71:461–77. [PubMed: 19040644]
98. Laurent CE, Delfino FJ, Cheng HY, Smithgall TE. The human c-Fes tyrosine kinase binds tubulin and microtubules through separate domains and promotes microtubule assembly. *Mol Cell Biol.* 2004; 24:9351–8. [PubMed: 15485904]
99. Teckchandani AM, Birukova AA, Tar K, Verin AD, Tsygankov AY. The multidomain protooncogenic protein c-Cbl binds to tubulin and stabilizes microtubules. *Exp Cell Res.* 2005; 306:114–27. [PubMed: 15878338]
100. Elm C, Braathen R, Bergmann S, Frank R, Vaerman JP, Kaetzel CS, Chhatwal GS, Johansen FE, Hammerschmidt S. Ectodomains 3 and 4 of human polymeric Immunoglobulin receptor (hplgR) mediate invasion of Streptococcus pneumoniae into the epithelium. *J Biol Chem.* 2004; 279:6296–304. [PubMed: 14660617]
101. Gordon SB, Molyneux ME, Boeree MJ, Kanyanda S, Chaponda M, Squire SB, Read RC. Opsonic phagocytosis of Streptococcus pneumoniae by alveolar macrophages is not impaired in human immunodeficiency virus-infected Malawian adults. *J Infect Dis.* 2001; 184:1345–9. [PubMed: 11679928]




Figure 1. Bacterial effector proteins that destabilize host microtubules. The mechanism of action of effector proteins that has been demonstrated or hypothesized is illustrated. The possible benefits of host microtubule destruction for the pathogen have also been depicted in the figure.




Figure 2. Bacterial effector proteins that stabilize host microtubules. The known mechanism of action of effector proteins and the benefits of host microtubule stabilization for the pathogen have been depicted in the figure. MT, microtubule; BCV, *Brucella*-containing vacuoles; SCV, *Salmonella*-containing vacuole; Ply, pneumolysin; CDT, *Clostridium difficile* toxin.




Figure 3. TcpB co-localizes with host microtubules. HEK-293 cells were transfected with pCMV-HA-TcpB plasmid and stained for HA-TcpB (A), tubulin (B), and merged (C). Scale bar, 5 μm .




Figure 4.

TcpB enhances the rate of microtubule polymerization like paclitaxel (Taxol). *In vitro* microtubule polymerization assay in the presence of purified TcpB (0.5 mg/ml) or paclitaxel (5 μ M). TcpB could efficiently enhance the nucleation and growth phases of microtubule polymerization and the total amount of microtubules polymerized similar to the microtubule stabilization drug paclitaxel. Adapted from ref. (87).

Table 1

Bacterial effector proteins that modulate microtubule dynamics.

Pathogen	Effector proteins	References
Microtubule destabilizers		
<i>Shigella flexneri</i>	VirA	(29–31)
Enteropathogenic <i>Escherichia coli</i>	EspG and EspG2	(36–38)
<i>Citrobacter rodentium</i>	EspG	(44)
<i>Chlamydia</i>	CopN	(49–51)
<i>Edwardsiella tarda</i>	EseG	(53)
<i>Listeria monocytogenes</i>	ActA	(60, 67, 72)
Microtubule stabilizers		
<i>Salmonella enterica</i>	SifA, SseF, SseG	(54, 77)
<i>Brucella</i> spp.	TcpB/Bpt1	(83–85)
<i>Clostridium difficile</i>	CDT	(89)
<i>Clostridium botulinum</i>	C2	(89)
<i>Clostridium perfringens</i>	Iota toxin	(89)
<i>Streptococcus pneumoniae</i>	Pneumolysin	(95)